New and experimental HIV treatments: latest news

New and experimental HIV treatments resources

New and experimental HIV treatments features

New and experimental HIV treatments in your own words

New and experimental HIV treatments news from aidsmap

More news

New and experimental HIV treatments news selected from other sources

  • Six questions about HIV/AIDS that deserve more attention

    As HIV investigators work to control and eradicate the virus worldwide, certain myths or misconceptions about the disease have been embraced, whereas other concepts with merit have been left relatively unexplored, argues American HIV/AIDS researcher Jay Levy, M.D., in a Trends in Molecular Medicine commentary. He calls on fellow researchers to continue questioning and not to lose sight of alternative strategies that could ultimately lead to a sustainable, long-term solution to HIV infection.

    15 April 2015 | Eurekalert Inf Dis
  • Mechanism of action of ABIVAX’s First-in-class anti-HIV drug published today in peer-reviewed journal Retrovirology

    ABX464 blocks viral replication by preventing the export of viral RNA from the nucleus to the cytoplasm in infected cells. This transport is normally mediated by a viral protein called Rev, and the activity of Rev is efficiently inhibited by ABX464. Never targeted before, Rev has been postulated of potential interest for HIV treatment for some time, but ABX464 is the first molecule under development aimed at inhibiting it.

    14 April 2015 | ABIVAX press release
  • Editing HIV out of our genome with CRISPR

    In an attempt to render latent HIV completely harmless, UMass Medical School researchers are using CRISPR/Cas9, a powerful gene editing tool, to develop a novel technology that can potentially cut the DNA of the latent virus out of an infected cell.

    13 April 2015 | University of Massacusetts Medical Schoool press release
  • Broadly Neutralizing Antibody Suppresses HIV in Clinical Trial

    There is now intense interest in learning whether the blossoming array of broadly neutralizing antibodies (bNAbs) can be put to therapeutic and preventive use. A paper published yesterday in Nature describes encouraging results from a phase I trial involving the bNAb 3BNC117. Reflecting the level of interest in the topic, the paper has attracted extensive press coverage.

    10 April 2015 | TAG
  • In first human study, new antibody therapy shows promise in suppressing HIV infection

    The new study, conducted in Michel Nussenzweig’s Laboratory of Molecular Immunology, finds that administration of a potent antibody, called 3BNC117, can catch HIV off guard and reduce viral loads.

    09 April 2015 | Rockefeller University press release
  • Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment

    Gilead Sciences, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for two doses of an investigational fixed-dose combination of emtricitabine and tenofovir alafenamide (200/10 mg and 200/25 mg) (F/TAF) for the treatment of HIV-1 infection in adults and pediatric patients age 12 years and older, in combination with other HIV antiretroviral agents.

    08 April 2015 | Gilead press release
  • New lead against HIV could finally hobble the virus’s edge

    Scientists at Emory University, in partnership with the pharmaceutical company Bristol-Myers Squibb, have found compounds that block the human CCR5 and CXCR4 co-receptors for HIV and also HIV reverse transcriptase, an enzyme that’s key to the virus’s ability to copy itself.

    24 March 2015 | American Chemical Society
  • HIV treatment: New inexpensive agents can block virus ability to replicate and develop resistance

    New and affordable drugs that check the HIV virus from developing resistance are in progress, according to scientists who will present their findings at the 249th National Meeting & Exposition of the American Chemical Society (ACS) in Denver.

    20 March 2015 | International Business Times
  • Beware Of Sangamo: 20-Year History Of Failures, Misadventures In HIV, And Flawed Approach In B-Thalassemia

    Sangamo's purportedly ground-breaking results in HIV with SB-728 do not stand up under close examination. SB-728 has not shown any indication that it can provide a "functional cure" for HIV, does not compare well to today's standard of care, and cannot find a partner. Sangamo refuses to conduct studies that rigorously assess whether their drugs work. This includes the inclusion of a control arm so assiduously avoided by Sangamo's management.

    10 March 2015 | Seeking Alpha
  • 48-week analysis of investigational HIV-1 attachment inhibitor paves way for Phase III trial initiation

    Phase III trial now underway for novel therapy for heavily treatment-experienced HIV-1 patients. Binding directly to the HIV virus, BMS-663068 is the first investigational antiretroviral designed to prevent initial viral attachment to host CD4+ T cells and entry into host immune cells. Phase III trial now underway for novel therapy for heavily treatment-experienced HIV-1 patients Binding directly to the HIV virus, BMS-663068 is the first investigational antiretroviral designed to prevent initial viral attachment to host CD4+ T cells and entry into host immune cells PRINCETON, N.J., February 25, 2015--Bristol-Myers Squibb Company (NYSE:BMY) today announced data...

    26 February 2015 | Bristol Myers Squibb press release
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.